scholarly journals Neurofilament Heavy polypeptide CpG island methylation associates with prognosis of renal cell carcinoma and prediction of antivascular endothelial growth factor therapy response

2014 ◽  
Vol 3 (2) ◽  
pp. 300-309 ◽  
Author(s):  
Natalia Dubrowinskaja ◽  
Kai Gebauer ◽  
Inga Peters ◽  
Jörg Hennenlotter ◽  
Mahmoud Abbas ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Growth Factor ◽  
Renal Cell ◽  
Cpg Island ◽  
Therapy Response ◽  
Antivascular Endothelial Growth Factor ◽  
Factor Therapy ◽  
Cpg Island Methylation ◽  
Growth Factor Therapy ◽  
Endothelial Growth Factor

scholarly journals Is It Safe to Restart Antivascular Endothelial Growth Factor Therapy in Patients with Renal Cell Carcinoma after Cardiac Ischemia?

2015 ◽  
Vol 2015 ◽  
pp. 1-4 ◽  
Author(s):  
Bo Zhao ◽  
Laura S. Wood ◽  
Karen James ◽  
Brian I. Rini
Keyword(s):  
Renal Cell Carcinoma ◽  
Growth Factor ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Cardiac Ischemia ◽  
Vascular Endothelial ◽  
Cardiac Events ◽  
Factor Therapy ◽  
Growth Factor Therapy ◽  
Endothelial Growth Factor

Agents targeting vascular endothelial growth factor (VEGF) represent active drugs in treating patients with advanced renal cell carcinoma (RCC). Studies have shown that sunitinib and axitinib can be associated with cardiac toxicity. Whether these agents should be restarted in patients who experience cardiac ischemia remains uncertain. Here, we present three patients with metastatic RCC who restarted sunitinib or axitinib after intervention of active ischemic cardiac disease without causing subsequent relevant cardiac events. This experience suggests that these agents can be continued after management of cardiac ischemia.

scholarly journals Ten-year outcomes of antivascular endothelial growth factor therapy in neovascular age-related macular degeneration

Eye ◽  
2020 ◽  
Vol 34 (10) ◽  
pp. 1888-1896 ◽  
Author(s):  
Shruti Chandra ◽  
Cristina Arpa ◽  
Deepthy Menon ◽  
Hagar Khalid ◽  
Robin Hamilton ◽  
...  
Keyword(s):  
Growth Factor ◽  
Macular Degeneration ◽  
Age Related Macular Degeneration ◽  
Age Related ◽  
Antivascular Endothelial Growth Factor ◽  
Factor Therapy ◽  
Growth Factor Therapy ◽  
Endothelial Growth Factor

Treatment of Eyes With Diabetic Macular Edema That Had a Suboptimal Response to Antivascular Endothelial Growth Factor Therapy: 2-mg Intravitreal Triamcinolone Acetonide vs 0.7-mg Dexamethasone Implant

2020 ◽  
Vol 4 (5) ◽  
pp. 372-376
Author(s):  
Brandon Kuley ◽  
Philip P. Storey ◽  
Maitri Pancholy ◽  
Turner D. Wibbelsman ◽  
Anthony Obeid ◽  
...  
Keyword(s):  
Growth Factor ◽  
Macular Edema ◽  
Diabetic Macular Edema ◽  
Intravitreal Triamcinolone ◽  
Treatment Groups ◽  
Antivascular Endothelial Growth Factor ◽  
Factor Therapy ◽  
Growth Factor Therapy ◽  
Endothelial Growth Factor

Purpose: This article compares 2-mg intravitreal triamcinolone (IVT) and 0.7-mg dexamethasone (DEX) implant for the treatment of diabetic macular edema in eyes that had a suboptimal response to antivascular endothelial growth factor therapy. Methods: A single-center, retrospective review was conducted of patients receiving either IVT between January 1, 2013, and January 1, 2018, or patients receiving DEX between October 1, 2015, and January 1, 2018. Visual acuity and central macular thickness (CMT) were recorded at visit of first injection and all subsequent visits. Results: Twenty-five eyes were included in the DEX group and 32 eyes were included in the IVT group. Change in vision from baseline was similar between DEX and IVT at 6-month follow-up (1.1 lines vs 2.3 lines, respectively; P = .24). Mean decrease in CMT from baseline was not different at 6-month follow-up (DEX: 120 µm vs IVT: 185 µm; P = .17). Conclusions: DEX and 2-mg IVT both achieved improvement in vision and CMT with no significant differences between treatment groups at 6-month follow-up.

Sign in / Sign up

Export Citation Format

Share Document